Natco Pharma Ltd (NATCOPHARM) – Strategy, SWOT and Corporate Finance Report

Natco Pharma Ltd (NATCOPHARM) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Natco Pharma Ltd (Natco Pharma) focuses on the discovery, development, manufacturing, and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosages in capsule, injection and tablet forms. Its products are indicated to treat multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn's disease, hypertension, myelodysplastic syndrome, prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) in the domestic and international markets. It operates API and finished dosage facilities and a research center in India. The company operates in India, the US, Canada, and Europe. Natco Pharma is headquartered in Hyderabad, Telangana, India.

Scope

• Detailed information on Natco Pharma Ltd required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Natco Pharma Ltd in the form of a SWOT analysis

• An in-depth view of the business model of Natco Pharma Ltd including a breakdown and examination of key business segments

• News about Natco Pharma Ltd, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Natco Pharma Ltd and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Natco Pharma Ltd as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Natco Pharma Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Suven Life Sciences Ltd

Piramal Enterprises Ltd

Medicamen Biotech Ltd

Jubilant Pharmova Ltd

Divi's Laboratories Ltd

Biocon Ltd

Suven Life Sciences Ltd

Divi's Laboratories Ltd

Biocon Ltd

Piramal Enterprises Ltd

Medicamen Biotech Ltd

Jubilant Pharmova Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Natco Pharma Ltd - Key Facts

Natco Pharma Ltd - Key Employees

Natco Pharma Ltd - Key Employee Biographies

Natco Pharma Ltd - Major Products and Services

Natco Pharma Ltd - History

Natco Pharma Ltd - Company Statement

Natco Pharma Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 – Company Analysis

Company Overview

Natco Pharma Ltd - Business Description

Business Segment: Agro Chemicals

Overview

Performance

Business Segment: Pharmaceuticals

Overview

Performance

Key Stats

Geographical Segment: India

Performance

Geographical Segment: Rest of the world

Performance

Geographical Segment: USA

Performance

R&D Overview

Natco Pharma Ltd - Corporate Strategy

Natco Pharma Ltd - SWOT Analysis

SWOT Analysis - Overview

Natco Pharma Ltd - Strengths

Natco Pharma Ltd - Weaknesses

Natco Pharma Ltd - Opportunities

Natco Pharma Ltd - Threats

Natco Pharma Ltd - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Natco Pharma Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments

Jun 15, 2023: Natco’s Vizag Formulation Facility Receives Establishment Inspection Report (EIR)

Apr 20, 2023: NATCO Pharma : Outcome of Board Meeting

Jan 04, 2023: Zhongchao announces drug distributorship in China of Indian generic drugs of Natco Pharma

Dec 05, 2022: Natco receives favourable judgement, FMC appeal dismissed

Aug 09, 2022: Natco Pharma Unaudited Financial Results For The Quarter Ended 30Th June, 2022 and Interim Dividend

Aug 09, 2022: Natco Pharma announces Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 30Th June, 2022 And Interim Dividend

May 24, 2022: Edelweiss Securities Invitation to Natco Pharma Q4 FY22 Earnings call

May 23, 2022: NATCO Pharma announces legal update

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Natco Pharma Ltd, Key Facts

Natco Pharma Ltd, Key Employees

Natco Pharma Ltd, Key Employee Biographies

Natco Pharma Ltd, Major Products and Services

Natco Pharma Ltd, History

Natco Pharma Ltd, Other Locations

Natco Pharma Ltd, Subsidiaries

Natco Pharma Ltd, Joint Venture

Natco Pharma Ltd, Key Competitors

Natco Pharma Ltd, Ratios based on current share price

Natco Pharma Ltd, Annual Ratios

Natco Pharma Ltd, Annual Ratios (Cont…1)

Natco Pharma Ltd, Annual Ratios (Cont…2)

Natco Pharma Ltd, Interim Ratios

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Natco Pharma Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Natco Pharma Ltd, Performance Chart (2019 – 2023)

Natco Pharma Ltd, Ratio Charts

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports